227 related articles for article (PubMed ID: 34191861)
1. Temporal determinants of tumour response to neoadjuvant rectal radiotherapy.
Koo K; Ward R; Smith RL; Ruben J; Carne PWG; Elsaleh H
PLoS One; 2021; 16(6):e0254018. PubMed ID: 34191861
[TBL] [Abstract][Full Text] [Related]
2. Does chronomodulated radiotherapy improve pathological response in locally advanced rectal cancer?
Squire T; Buchanan G; Rangiah D; Davis I; Yip D; Chua YJ; Rich T; Elsaleh H
Chronobiol Int; 2017; 34(4):492-503. PubMed ID: 28353363
[TBL] [Abstract][Full Text] [Related]
3. [Analysis on efficacy and safety of total neoadjuvant therapy in patients with locally advanced rectal cancer with high risk factors].
Ouyang GL; Meng WJ; Shu P; Deng XB; Wu B; Jiang D; Zhuang H; Shen YL; Zhou ZG; Wang ZQ; Wang X
Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Apr; 22(4):349-356. PubMed ID: 31054549
[No Abstract] [Full Text] [Related]
4. Intermediate-fraction neoadjuvant radiotherapy for rectal cancer.
Zhan T; Gu J; Li M; Du C
Dis Colon Rectum; 2013 Apr; 56(4):422-32. PubMed ID: 23478609
[TBL] [Abstract][Full Text] [Related]
5. Effect of adding mFOLFOX6 after neoadjuvant chemoradiation in locally advanced rectal cancer: a multicentre, phase 2 trial.
Garcia-Aguilar J; Chow OS; Smith DD; Marcet JE; Cataldo PA; Varma MG; Kumar AS; Oommen S; Coutsoftides T; Hunt SR; Stamos MJ; Ternent CA; Herzig DO; Fichera A; Polite BN; Dietz DW; Patil S; Avila K;
Lancet Oncol; 2015 Aug; 16(8):957-66. PubMed ID: 26187751
[TBL] [Abstract][Full Text] [Related]
6. Comparison of pathological complete response rates after neoadjuvant short-course radiotherapy or chemoradiation followed by delayed surgery in locally advanced rectal cancer.
Hoendervangers S; Couwenberg AM; Intven MPW; van Grevenstein WMU; Verkooijen HM
Eur J Surg Oncol; 2018 Jul; 44(7):1013-1017. PubMed ID: 29650419
[TBL] [Abstract][Full Text] [Related]
7. Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
Rödel C; Graeven U; Fietkau R; Hohenberger W; Hothorn T; Arnold D; Hofheinz RD; Ghadimi M; Wolff HA; Lang-Welzenbach M; Raab HR; Wittekind C; Ströbel P; Staib L; Wilhelm M; Grabenbauer GG; Hoffmanns H; Lindemann F; Schlenska-Lange A; Folprecht G; Sauer R; Liersch T;
Lancet Oncol; 2015 Aug; 16(8):979-89. PubMed ID: 26189067
[TBL] [Abstract][Full Text] [Related]
8. Neoadjuvant-intensified treatment for rectal cancer: time to change?
Musio D; De Felice F; Bulzonetti N; Guarnaccia R; Caiazzo R; Bangrazi C; Raffetto N; Tombolini V
World J Gastroenterol; 2013 May; 19(20):3052-61. PubMed ID: 23716984
[TBL] [Abstract][Full Text] [Related]
9. [Comparison of short-term efficacy and perioperative safety between neoadjuvant therapy and total neoadjuvant therapy in patients with locally advanced rectal cancer].
Zhai ZW; Zhang KN; Wang C; Han JG; Ma HC; Wei GH; Yang Y; Wang ZJ
Zhonghua Wei Chang Wai Ke Za Zhi; 2020 Mar; 23(3):274-280. PubMed ID: 32192307
[No Abstract] [Full Text] [Related]
10. Tumour regression grading in the evaluation of tumour response after different preoperative radiotherapy treatments for rectal carcinoma.
Vironen J; Juhola M; Kairaluoma M; Jantunen I; Kellokumpu I
Int J Colorectal Dis; 2005 Sep; 20(5):440-5. PubMed ID: 15856263
[TBL] [Abstract][Full Text] [Related]
11. A phase I/II trial of three-dimensionally planned concurrent boost radiotherapy and protracted venous infusion of 5-FU chemotherapy for locally advanced rectal carcinoma.
Myerson RJ; Valentini V; Birnbaum EH; Cellini N; Coco C; Fleshman JW; Gambacorta MA; Genovesi D; Kodner IJ; Picus J; Ratkin GA; Read TE
Int J Radiat Oncol Biol Phys; 2001 Aug; 50(5):1299-308. PubMed ID: 11483342
[TBL] [Abstract][Full Text] [Related]
12. Importance of tumor regression assessment in predicting the outcome in patients with locally advanced rectal carcinoma who are treated with preoperative radiotherapy.
Bouzourene H; Bosman FT; Seelentag W; Matter M; Coucke P
Cancer; 2002 Feb; 94(4):1121-30. PubMed ID: 11920483
[TBL] [Abstract][Full Text] [Related]
13. Complete pathologic response following preoperative chemoradiation therapy for middle to lower rectal cancer is not a prognostic factor for a better outcome.
Pucciarelli S; Toppan P; Friso ML; Russo V; Pasetto L; Urso E; Marino F; Ambrosi A; Lise M
Dis Colon Rectum; 2004 Nov; 47(11):1798-807. PubMed ID: 15622571
[TBL] [Abstract][Full Text] [Related]
14. Regression of rectal cancer with radiotherapy with or without concurrent capecitabine--optimising the timing of surgical resection.
Dhadda AS; Zaitoun AM; Bessell EM
Clin Oncol (R Coll Radiol); 2009 Feb; 21(1):23-31. PubMed ID: 19027272
[TBL] [Abstract][Full Text] [Related]
15. Tumour regression grading after chemoradiotherapy for locally advanced rectal cancer: a near pathologic complete response does not translate into good clinical outcome.
Swellengrebel HA; Bosch SL; Cats A; Vincent AD; Dewit LG; Verwaal VJ; Nagtegaal ID; Marijnen CA
Radiother Oncol; 2014 Jul; 112(1):44-51. PubMed ID: 25018000
[TBL] [Abstract][Full Text] [Related]
16. The prognostic value of lymph node metastases and tumour regression grade in rectal cancer patients treated with long-course preoperative chemoradiotherapy.
Lindebjerg J; Spindler KL; Ploen J; Jakobsen A
Colorectal Dis; 2009 Mar; 11(3):264-9. PubMed ID: 18573119
[TBL] [Abstract][Full Text] [Related]
17. Outcomes of neoadjuvant chemoradiotherapy followed by total mesorectal excision surgery for locally advanced rectal cancer: a single-institution experience.
Tseng MSF; Zheng H; Ng IWS; Leong YH; Leong CN; Yong WP; Cheong WK; Tey JCS
Singapore Med J; 2018 Jun; 59(6):305-310. PubMed ID: 29167909
[TBL] [Abstract][Full Text] [Related]
18. An interval >7 weeks between neoadjuvant therapy and surgery improves pathologic complete response and disease-free survival in patients with locally advanced rectal cancer.
Tulchinsky H; Shmueli E; Figer A; Klausner JM; Rabau M
Ann Surg Oncol; 2008 Oct; 15(10):2661-7. PubMed ID: 18389322
[TBL] [Abstract][Full Text] [Related]
19. [Practical neoadjuvant and adjuvant therapies for rectal cancer. How many patients are actually recruited in multimodality therapy concepts? An analysis of the Tumour Centre Schwerin].
Sauer J; Sobolewski K; Dommisch K
Zentralbl Chir; 2009 Sep; 134(5):450-4. PubMed ID: 19757345
[TBL] [Abstract][Full Text] [Related]
20. Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial.
Bahadoer RR; Dijkstra EA; van Etten B; Marijnen CAM; Putter H; Kranenbarg EM; Roodvoets AGH; Nagtegaal ID; Beets-Tan RGH; Blomqvist LK; Fokstuen T; Ten Tije AJ; Capdevila J; Hendriks MP; Edhemovic I; Cervantes A; Nilsson PJ; Glimelius B; van de Velde CJH; Hospers GAP;
Lancet Oncol; 2021 Jan; 22(1):29-42. PubMed ID: 33301740
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
